Abstract
Roflumilast is a specific PDE4 inhibitor being developed by Altana Pharma (formerly known as Byk Gulden) for the potential treatment of asthma and chronic obstructive pulmonary disease [312928].
MeSH terms
-
Aminopyridines / adverse effects
-
Aminopyridines / chemical synthesis
-
Aminopyridines / pharmacokinetics
-
Aminopyridines / pharmacology
-
Aminopyridines / therapeutic use*
-
Animals
-
Anti-Asthmatic Agents / adverse effects
-
Anti-Asthmatic Agents / chemical synthesis
-
Anti-Asthmatic Agents / pharmacokinetics
-
Anti-Asthmatic Agents / pharmacology
-
Anti-Asthmatic Agents / therapeutic use*
-
Benzamides / adverse effects
-
Benzamides / chemical synthesis
-
Benzamides / pharmacokinetics
-
Benzamides / pharmacology
-
Benzamides / therapeutic use*
-
Bronchoconstriction / drug effects
-
Bronchodilator Agents / adverse effects
-
Bronchodilator Agents / chemical synthesis
-
Bronchodilator Agents / pharmacokinetics
-
Bronchodilator Agents / pharmacology
-
Bronchodilator Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cyclopropanes
-
Humans
-
Leukocytes / drug effects
-
Leukocytes / enzymology
-
Phosphodiesterase Inhibitors / adverse effects
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / pharmacology
-
Phosphodiesterase Inhibitors / therapeutic use*
-
Structure-Activity Relationship
Substances
-
Aminopyridines
-
Anti-Asthmatic Agents
-
Benzamides
-
Bronchodilator Agents
-
Cyclopropanes
-
Phosphodiesterase Inhibitors
-
Roflumilast